Moderna Signs Five-Year MoU with Mexico to Transfer mRNA Tech, Supply 10M Doses
Moderna signed a five-year MoU with Mexico’s government and Liomont to transfer mRNA technology and enable local production of its COVID-19 vaccine mRNA-1273 plus access to its respiratory portfolio. The agreement covers supply of up to 10 million 2025-2026 COVID-19 vaccine doses and joint clinical R&D under Plan Mexico.
1. Strategic Agreement Overview
Moderna entered a five-year strategic agreement with the Mexican government, Laboratorios Liomont, and BIRMEX to bolster health sovereignty and establish a resilient mRNA ecosystem. The MoU underpins Mexico’s Plan Mexico initiative by securing access to Moderna’s respiratory vaccine portfolio.
2. Technology Transfer and Local Manufacturing
Under the agreement, Moderna will transfer proprietary mRNA manufacturing processes to Liomont’s state-of-the-art facilities. This will enable domestic production of the mRNA-1273 COVID-19 vaccine, reducing reliance on international supply chains.
3. Vaccine Supply Commitments
The contract includes the supply of up to 10 million doses of Moderna’s 2025-2026 COVID-19 vaccine and access to its broader respiratory vaccine line. This commitment follows COFEPRIS approval for use in individuals aged six months and older.
4. R&D Collaboration and Preparedness
Moderna and Mexican authorities will collaborate on locally driven clinical research programs aligned with national health priorities. The partnership aims to strengthen Mexico’s pandemic preparedness framework through joint development and regulatory initiatives.